Chamaeleo Pharma Appoints Han Van 't Klooster As Vice President Of Commercial Operations

Diegem, Belgium, March 2, 2015 / B3C newswire / - Chamaeleo Pharma NV, a Belgium-based oncology company, announced today that Han Van 't Klooster has joined Chamaeleo as Vice President of Commercial Operations. Han will be a member of Chamaeleo's Management team and will be responsible for the market access and commercial launch of the Company's lead product Fosfestrol for the treatment of advanced prostate cancer.

Han Van 't Klooster has over 20 years of business experience in the pharmaceutical industry. Prior to joining Chamaeleo, he was the General Manager of Pharmion Europe (acquired by Celgene). Before Pharmion, Han was the International Marketing Director Oncology at Chiron Corporation (acquired by Novartis) where he was responsible for the commercialization of two oncology products. Han started his career at AstraZeneca as a Product Manager.

"We are pleased to welcome Han Van 't Klooster into our Management team," said Laurens G. Theunis, CEO of Chamaeleo. "Han's vast experience in oncology drug commercialization is an important asset that will help our company to move to the next level".

"I'm very excited to join Chamaeleo at this important point of its development," said Han Van 't Klooster. "During the past few years, Chamaeleo has rapidly developed a unique product portfolio in oncology and I'm very much looking forward to working together with the team towards our first product registration and sales".

About Chamaeleo

Chamaeleo is a privately-held pharmaceutical company engaged in the development and commercialization of drugs addressing unmet medical needs in multiple cancer indications. The Company's product portfolio includes three products: Fosfestrol for advanced prostate cancer (registration phase under preparation), and Fosfestrol-plus and Sulfestrol for multiple cancers (development phase). Chamaeleo was founded in 2011 and is based in Belgium with additional operations in The Netherlands.

Laurens G. Theunis
Chamaeleo Pharma NV
Phone: +32 478 244 451
Email: [email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.